Delineation of the genomic complexities of malignant pleural mesothelioma (MPM) has lagged behind other malignancies. Zhang et al. meaningfully add to our understanding of MPM, and their findings emphasize the need to combine drug development efforts with appropriate predictive biomarkers.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985484 | PMC |
http://dx.doi.org/10.1038/s41467-021-22142-y | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!